Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

NCT03520686 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

102

Enrollment

INDUSTRY

Sponsor class

Stopped There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: NAI + Pembrolizumab
DRUG: NAI + Nivolumab + Ipilimumab
DRUG: Pembrolizumab
DRUG: NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel
DRUG: Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice)
DRUG: Cisplatin/carboplatin and pemetrexed plus pembrolizumab.
DRUG: Cisplatin/carboplatin and pemetrexed plus atezolizumab.
DRUG: Carboplatin and paclitaxel plus atezolizumab and bevacizumab.
DRUG: Carboplatin and nab-paclitaxel plus atezolizumab.
DRUG: NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel

Sponsor

ImmunityBio, Inc.